Abstract | BACKGROUND AND PURPOSE: The efficacy of the antiplatelet agent triflusal for prevention of vascular events after stroke has been reported in a pilot study. However, there is a need to confirm those results in a larger study. METHODS: RESULTS: Of 2113 patients, 1058 received triflusal and 1055 aspirin. The mean follow-up period was 30.1 months. The incidence of combined end point (13.1% for triflusal, 12.4% for aspirin) as well the survival analysis (hazard ratio [HR] for triflusal versus aspirin, 1.09; 95% CI, 0.85 to 1.38) showed no differences between groups. The incidence of nonfatal stroke (HR, 1.09; 95% CI, 0.82 to 1.44), nonfatal acute myocardial infarction (HR, 0.95; 95% CI, 0.46 to 1.98,) and vascular death (HR, 1.22; 95% CI, 0.75 to 1.96) was also similar. A significantly higher incidence of major hemorrhages in the aspirin group was recorded (HR, 0.48; 95% CI, 0.28 to 0.82). The overall incidence of hemorrhage was significantly lower in the triflusal group (16.7% versus 25.2%) (odds ratio, 0.76; 95% CI, 0.67 to 0.86; P<0.001). CONCLUSIONS: This study failed to show significantly superior efficacy of triflusal over aspirin in the long-term prevention of vascular events after stroke, but triflusal was associated with a significantly lower rate of hemorrhagic complications.
|
Authors | Jordi Matías-Guiu, José M Ferro, José Alvarez-Sabín, Ferran Torres, M Dolores Jiménez, Aida Lago, Teresa Melo, TACIP Investigators |
Journal | Stroke
(Stroke)
Vol. 34
Issue 4
Pg. 840-8
(Apr 2003)
ISSN: 1524-4628 [Electronic] United States |
PMID | 12649515
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Salicylates
- triflusal
- Aspirin
|
Topics |
- Aspirin
(adverse effects, therapeutic use)
- Cardiovascular Diseases
(epidemiology, mortality, prevention & control)
- Cerebral Infarction
(diagnosis, drug therapy)
- Double-Blind Method
- Female
- Hemorrhage
(chemically induced)
- Humans
- Incidence
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology)
- Platelet Aggregation Inhibitors
(adverse effects, therapeutic use)
- Salicylates
(adverse effects, therapeutic use)
- Secondary Prevention
- Stroke
(epidemiology, prevention & control)
- Survival Analysis
|